New results show potential of New Class of Drug Therapy for Alzheimer’s Disease and Age-Related Cognitive Impairment
VANCOUVER, July 16, 2012 /PRNewswire/ – Data presented today at the Alzheimer’s
Association International Conference in Vancouver, Ca. demonstrate that
that a new class of drugs has potential to improve synaptic function in
the central nervous system in animal models of Alzheimer’s disease, an
effect that is anticipated to lead to improved cognition in Alzheimer’s
disease and age-related cognitive impairment.
Dr. Lawren VandeVrede, of the University of Illinois College of
Pharmacy, Chicago, provided an overview of the therapeutic potential of
a new class of compounds known as ‘nomethiazoles’. This therapeutic
class was initially defined in the laboratory of Prof. Greg Thatcher
while at Queen’s University, Kingston, Ontario. Professor Thatcher now
holds the Hans W. Vahlteich Chair of Medicinal Chemistry in the
Department of Medicinal Chemistry and Pharmacognosy at the University
of Illinois College of Pharmacy, Chicago. Dr. VandeVrede, an MD/PhD
trainee in Prof. Thatcher’s laboratory, has continued research on this
new class of therapy.
The data presented by Dr. VandeVrede focuses on sGC-1061, one of this
new class of compounds. sGC-1061 has been selected as a drug candidate,
and the process of clinical development has already begun. A prototype
sustained-release formulation has been developed, following a Phase-l
clinical trial, which demonstrated very high bioavailability for
sGC-1061. Based on preclinical assessments of prototype formulations,
this development program is now staged to return to clinical
evaluations under an IND in the USA. Following Phase-1 PK studies,
sGC-1061will be poised to enter Phase-2 proof of concept evaluations in
According to Dr. Elliott J. Mufson, Alla and Solomon Jesmer Chair in
Aging at Chicago’s Rush University Medical Center, “Preliminary
evidence in a transgenic animal model of Alzheimer’s Disease indicates
that this compound has potential to improve synaptic
efficiency providing evidence for therapeutic potential…”‘.
Clinical Phase-ll proof of concept evaluations in target populations are
the next stage in development of this new approach to therapy for
Alzheimer’s disease, which differs significantly from the dominant
efforts focused on specific targeting of amyloid-beta. These approaches
have failed in clinical trials. Nomethiazoles are a potentially
important and new disease-modifying approach to a complex problem.
Although animal models are imperfect predictors of clinical success,
data presented by Dr VandeVrede shows that the mechanism of action of
these agents improves cognition and lowers amyloid-beta and tau in two
Alzheimer’s animal models.
Professor Thatcher’s work on nomethiazoles has been licensed from
Queen’s University’s PARTEQ Innovations and the University of Illinois
and is being developed by sGC Pharma Inc., an early stage company
headquartered in Wellesley MA. Dr. Doug Cowart of sGC Pharmaceuticals
indicated that the new formulation of sGC-1061 relies on recently
patented technology to assure that plasma concentrations remain in the
therapeutic range with once or twice daily dosage.
About sGC Pharma Inc.:
sGC Pharma is a biotechnology company dedicated to developing a drug to
improve cognition and memory in patients with Alzheimer’s disease (AD).
The company is headquartered in Wellesley, MA.
SOURCE sGC Pharma Inc.